Multiple myeloma accounts for about 10% of hematologic malignancies. It is one of the most intractable malignancies and is characterized by the presence of neoplastic terminally differentiated immunoglobulin-producing B lymphocytes (plasma cells) that de
Multiple myeloma (MM) is the most aggressive and prevalent primary malignant tumor within the blood system, and can be classified into grades RISS-I, II, and III. High-grade tumors are associated with decreased survival rates and increased recurrence rat
Overview of Effectiveness and Challenges in CAR T-cell Therapy for Multiple Myeloma.AManufacturing and Administration of CAR T-cells: This section highlights strategies for optimizing production and functionality, innovations in genetic modification, allogeneic CAR T-cell development, and early therapy impl...
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Multiple Myeloma Version 2.2023 — October 31, 2022 NCCN.org NCCN Guidelines for Patients® available at www.nccn.org/patients Continue Version 2.2023, 10/31/22 © 2022 National Comprehensive Cancer Network® (NCCN®), All ...
Many potential targets for myeloma cells are currently undergoing phase I/II clinical trials, and these off-the-shelf bispecific molecules are likely to become a critical part of the MM treatment landscape.#This article provides an overview of the latest advances in BsAbs i...
Experimental Hematology & Oncology (2022) 11:49 https://doi.org/10.1186/s40164-022-00303-z Experimental Hematology & Oncology REVIEW Open Access Metabolic cross‑talk within the bone marrow milieu: focus on multiple myeloma Inge Oudaert, Arne Van der Vreken, Anke Maes, ...
T-cell redirecting therapy (TCRT), specifically chimeric antigen receptor T-cell therapy (CAR T-cells) and bispecific T-cell engagers (TCEs) represent a remarkable advance in the treatment of multiple myeloma (MM). There are several products available around the world and several more in develo...
Multiple myeloma (MM) is a malignant disorder originating from plasma cells. Bortezomib (BTZ) resistance has become a huge obstacle to MM treatment. Herein, we elucidated the action of Kruppel-like factor 2 (KLF2), a crucial transcription factor (TF), on BTZ resistance of MM. Methods Two BT...
Multiple myeloma (MM) is an incurable malignancy of clonal plasma cells, characterized by high relapse rates and rapid development of drug resistance. The emergence of proteasome inhibitors has dramatically improved the therapeutic effect of MM; however, side effects and drug resistance still negatively...
Multiple myeloma (MM) is the second most common hematological cancer, characterized by the abnormal proliferation of plasma cells and contributes to 2% of cancer-related deaths in the United States [1]. Initially addressed with melphalan, advances in disease understanding have transformed the therapeuti...